Michael P. Dillon - 06 Jul 2021 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
SVP, Chief Scientific Officer
Signature
/s/ Jason Throne, as Attorney-in-Fact for Michael P. Dillon
Issuer symbol
IDYA
Transactions as of
06 Jul 2021
Net transactions value
-$22,978
Form type
4
Filing time
08 Jul 2021, 19:01:28 UTC
Previous filing
17 Jun 2021
Next filing
29 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $10,380 +1,500 +1.5% $6.92 100,289 06 Jul 2021 Direct
transaction IDYA Common Stock Sale $31,082 -1,400 -1.4% $22.20 98,889 06 Jul 2021 Direct F1, F2
transaction IDYA Common Stock Sale $2,276 -100 -0.1% $22.76 98,789 06 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -1,500 -3.3% $0.000000 44,500 06 Jul 2021 Common Stock 1,500 $6.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades in prices ranging from $21.70 to $22.5450, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.